Scan test to see tumor-support cells in pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a special imaging scan (a PET/CT with a tracer called 68Ga-FAPI-46) to look at “cancer-support” cells in people with localized pancreatic ductal adenocarcinoma. It may help doctors better understand the tumor and how it responds before surgery after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult age 18 or older
- You have confirmed pancreatic ductal adenocarcinoma (PDA) from a biopsy, or baseline scans that strongly suggest PDA
- Your cancer is localized, and you expect surgery after you receive initial chemo or treatment (neoadjuvant therapy)
- Your current health/activity level is fairly good (ECOG 0 to 2)
- You can sign consent and follow study instructions
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that uses a special tracer (FAPI) to get clearer images of pancreatic cancer. The goal is to find cancer earlier and better plan surgery or treatment.
This study tests a new type of PET scan that uses a radioactive tracer called FAPI-74 to find cancer spread in people with pancreatic cancer. The goal is to see if this scan can help doctors better plan treatment.
This trial uses a new imaging agent called 64Cu-DOTA A2 to help see pancreatic cancer on a PET scan. It may help doctors find cancer that has spread, without the need for surgery.
This study tests a new imaging agent (68Ga-FAPI-46) to see if it can better show the extent of pancreatic cancer before surgery. It may help doctors plan your surgery more accurately.
This trial uses a special PET scan (FAPi PET) to see if it can help spot pancreatic ductal adenocarcinoma better than standard scans. It may offer a more precise way to check the extent of the disease.
This trial tests a new imaging method called FAPI-PET to see if it can better detect pancreatic and bile duct cancers at an early stage. It may help doctors decide on the best treatment plan for you.
Hear when a new Resectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.